Mirati Therapeutics, Inc.
NASDAQ:MRTX
58.7 (USD) • At close January 22, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Mirati Therapeutics, Inc. |
Symbool | MRTX |
Munteenheid | USD |
Prijs | 58.7 |
Beurswaarde | 4,117,669,755 |
Dividendpercentage | 0% |
52-weken bereik | 27.3 - 64.41 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Charles M. Baum M.D., Ph.D. |
Website | https://www.mirati.com |
An error occurred while fetching data.
Over Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)